Lilly(Eli) & Co

+4.39 (+3.05%)
4:00:00 PM EDT: $148.46 -0.04 (-0.03%)

Lilly's Neutralizing Antibody Receives FDA Emergency Use Nod For Treatment Of Recently Diagnosed COVID-19

Published: 11/09/2020 23:41 GMT
Eli Lilly and Co (LLY) - Lilly's Neutralizing Antibody Bamlanivimab (ly-cov555) Receives FDA Emergency Use Authorization for the Treatment of Recently Diagnosed Covid-19.
Eli Lilly and Co - U.S. Government Will Allocate 300,000 Doses of Bamlanivimab to High-risk Patients, With No Out-of-pocket Costs for Medication.
Eli Lilly and Co - FDA Granted Eua for Co's Investigational Neutralizing Antibody Bamlanivimab (ly-cov555) 700 Mg.
Eli Lilly and Co - Eua Includes a Warning for Hypersensitivity Including Anaphylaxis and Infusion-related Reactions.
Eli Lilly - Will Begin Shipping Bamlanivimab Immediately to Amerisourcebergen, Which Will Distribute It As Directed by U.S. Government's Allocation Program.